2000
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N, Stenson W, Burr A, Zhao W, Kent J, Lefkowith J, Verburg K, Geis G. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. JAMA 2000, 284: 1247-1255. PMID: 10979111, DOI: 10.1001/jama.284.10.1247.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidAspirinCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacDouble-Blind MethodFemaleGastrointestinal DiseasesHumansIbuprofenIsoenzymesMaleMembrane ProteinsMiddle AgedOsteoarthritisPeptic UlcerProportional Hazards ModelsProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesSulfonamidesConceptsNonsteroidal anti-inflammatory drugsConventional nonsteroidal anti-inflammatory drugsCelecoxib Long-term Arthritis Safety StudyCOX-2-specific inhibitorsUlcer complicationsSymptomatic ulcersAnti-inflammatory drugsRheumatoid arthritisIncidence rateAspirin useLower incidenceChronic GI blood lossToxic effectsAdverse effectsCelecoxib-treated patientsUpper GI toxicityUpper GI ulcersGI blood lossInhibition of cyclooxygenaseGI intoleranceCardiovascular eventsGastrointestinal toxicityGI toxicityImportant toxic effectsStudy drugUpper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpoint
1998
Cognitive Outcome at 4½ Years of Very Low Birth Weight Infants Enrolled in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial
Ment L, Westerveld M, Makuch R, Vohr B, Allan W. Cognitive Outcome at 4½ Years of Very Low Birth Weight Infants Enrolled in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 1998, 102: 159-159. PMID: 9714645, DOI: 10.1542/peds.102.1.159.Peer-Reviewed Original Research
1996
Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial.
Ment L, Vohr B, Oh W, Scott D, Allan W, Westerveld M, Duncan C, Ehrenkranz R, Katz K, Schneider K, Makuch R. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 1996, 98: 714-8. PMID: 8885951, DOI: 10.1542/peds.98.4.714.Peer-Reviewed Original ResearchMeSH KeywordsCerebral HemorrhageChild DevelopmentChild, PreschoolChi-Square DistributionCyclooxygenase InhibitorsHumansIndomethacinInfantInfant, NewbornInfant, PrematureInfant, Premature, DiseasesInfant, Very Low Birth WeightIntelligence TestsNeurologic ExaminationUltrasonography, Doppler, TranscranialConceptsLow-dose indomethacinMonths' corrected ageIntraventricular hemorrhageCorrected ageNeurodevelopmental followLong-term neurodevelopmental followLow birth weight infantsLow birth weight neonatesBirth weight infantsMean gestational ageBirth weight neonatesStandard neurologic examinationAdverse cognitive outcomesIncidence of deafnessDose indomethacinWeight infantsPreterm infantsProspective trialWeight neonatesCranial ultrasoundEarly administrationNeurodevelopmental outcomesNeurologic examinationCerebral palsyGestational age